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Abstract
Background: Glucocorticoids, such as prednisolone, are widely used anti-inflammatory drugs, but therapy is
hampered by a broad range of metabolic side effects including skeletal muscle wasting and insulin resistance.
Therefore, development of improved synthetic glucocorticoids that display similar efficacy as prednisolone but
reduced side effects is an active research area. For efficient development of such new drugs, in vivo biomarkers,
which can predict glucocorticoid metabolic side effects in an early stage, are needed. In this study, we aim to
provide the first description of the metabolic perturbations induced by acute and therapeutic treatments with
prednisolone in humans using urine metabolomics, and to derive potential biomarkers for prednisolone-induced
metabolic effects.
Methods: A randomized, double blind, placebo-controlled trial consisting of two protocols was conducted in healthy
men. In protocol 1, volunteers received placebo (n = 11) or prednisolone (7.5 mg (n = 11), 15 mg (n = 13) or 30 mg
(n = 12)) orally once daily for 15 days. In protocol 2, volunteers (n = 6) received placebo at day 0 and 75 mg
prednisolone at day 1. We collected 24 h urine and serum samples at baseline (day 0), after a single dose (day 1) and
after prolonged treatment (day 15) and obtained mass-spectrometry-based urine and serum metabolic profiles.
Results: At day 1, high-dose prednisolone treatment increased levels of 13 and 10 proteinogenic amino acids in urine
and serum respectively, as well as levels of 3-methylhistidine, providing evidence for an early manifestation of
glucocorticoid-induced muscle wasting. Prednisolone treatment also strongly increased urinary carnitine derivatives at
day 1 but not at day 15, which might reflect adaptive mechanisms under prolonged treatment. Finally, urinary levels of
proteinogenic amino acids at day 1 and of N-methylnicotinamide at day 15 significantly correlated with the
homeostatic model assessment of insulin resistance and might represent biomarkers for prednisolone-induced insulin
resistance.
Conclusion: This study provides evidence that urinary metabolomics represents a noninvasive way of monitoring the
effect of glucocorticoids on muscle protein catabolism after a single dose and can derive new biomarkers of
glucocorticoid-induced insulin resistance. It might, therefore, help the development of improved synthetic
glucocorticoids.
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Background
Glucocorticoids (GCs), such as prednisolone, represent
the most important and frequently used class of anti-
inflammatory drugs. Today, GCs are the standard therapy
for reducing inflammation and immune activation in
asthma, allergy, and inflammatory and autoimmune
diseases, as well as in allotransplantation. In spite of
excellent efficacy, the clinical use of GCs is hampered by
a wide range of side effects, which are dependent on the
administered dose and duration of treatment [1]. Persis-
tent exposure to elevated levels of circulating GCs has
been associated with metabolic derangements including
the development of central adiposity, dyslipidemia, insu-
lin resistance, glucose intolerance, diabetes and skeletal
muscle wasting [1,2]. Both the anti-inflammatory and the
metabolic effects of GCs are mediated through their
binding to the GC receptor, which is ubiquitously
expressed in the human body. Upon ligand binding, the
GC receptor translocates into the nucleus where it
enables initiation (transactivation) or suppression (trans-
repression) of target gene transcription. Whereas transre-
pression largely accounts for the anti-inflammatory
action of GCs, transactivation of target genes involved in
the metabolism of glucose, lipids or proteins is mostly
implicated in adverse effects [3,4]. It has therefore long
been hypothesized that it should be possible to design
selective GC receptor agonists, with preserved transre-
pression actions and reduced transactivation effects,
allowing the preservation of beneficial effects while redu-
cing side effects [5,6]. However, development of selective
GC receptor agonists has so far only resulted in a few
compounds with improved therapeutic profiles in animal
models [5,7], but proof of concept in human remains to
be obtained. For evaluation and efficient development of
such improved synthetic GCs, in vivo biomarkers, which
can predict the occurrence of GC-induced side effects at
an early stage, are highly desired.
In that respect, global metabolic profiling, or metabolo-
mics, is an emerging technology that offers exciting pro-
mises. Metabolomics refers to the measurement of the
metabolite pool that exists within a system under a parti-
cular set of conditions. It has been extensively applied to
the area of drug research [8] and has proven useful for
deriving early organ-specific biomarkers [9] as well as per-
sonalized medicine biomarkers that can be used to predict
whether an individual will respond favorably or adversely
to a drug [10]. Potential advantages of metabolomics over
other omics platforms such as genomics, transcriptomics
and proteomics is that metabolic changes may be more
closely related to the immediate pathophysiologic state of
an individual and that minimally invasive biofluids such as
urine or blood are typically used.
To our knowledge, metabolomics has never been
applied to study the effects of GCs in humans. Given
the strong impact of these drugs on metabolism, we
expect, however, that metabolomics is a valuable tool to
derive early potential biomarkers for GC-induced meta-
bolic effects. In the present study, we describe the
untargeted mass spectrometry (MS)-based metabolomic
analysis of urine samples from a clinical study in which
healthy men were treated with increasing doses of pre-
dnisolone. In previous work on the same clinical trial, it
was reported that prednisolone had induced various
metabolic side effects in the volunteers, including insulin
resistance [11]. The aims of the present work are to
assess whether urine metabolomics can provide new
insights into the dose-range and timeline of predniso-
lone-induced metabolic perturbations and to derive
potential biomarkers of prednisolone-induced metabolic
side effects
Methods
Patient treatment and sample collection
This study was single-centered, double blinded, rando-
mized and placebo-controlled and consisted of two dis-
tinct parts. The two protocols enrolled healthy male
volunteers (age range 20 to 45 years, body mass index 22
to 30 kg/m2) as described previously [11]. Briefly, health
status and normal glucose metabolism were verified before
enrolment, and volunteers were matched for age and body
mass index between the treatment groups.
All participants provided written informed consent. This
study was approved by the Stichting Beoordeling Ethiek
Biomedisch Onderzoek and conducted in accordance with
the Declaration of Helsinki using good clinical practice.
Protocol 1: two-week study
Placebo was administered to all volunteers (n = 47) on day
0 at 0800 h (baseline). The following day at 0800 h, partici-
pants were randomly assigned to a treatment with 7.5 mg
(n = 11), 15 mg (n = 13) or 30 mg (n = 12) of prednisolone
or with placebo (n = 11). Medication was taken once daily
in the morning for a period of 15 days. This experimental
setting will be referred as ‘protocol 1’ (Figure S1A in
Additional file 1).
Urine samples were collected over 24 h on day 0, day 1
and day 15. No preservative was added to the urine sam-
ples. Fasting blood samples were collected in the morn-
ing of day 1, day 2 and day 16 prior to treatment.
Samples were frozen at -80°C after collection. Fasting
glucose and fasting insulin levels were measured and the
homeostatic model assessment of insulin resistance
(HOMA-IR) was calculated as previously described [11].
Protocol 2: acute study
The effects of acute treatment with prednisolone were
assessed in different participants. Placebo was adminis-
tered to all volunteers (n = 6) on day 0 at 0800 h (base-
line). The following day at 0800 h, volunteers were
treated with 75 mg prednisolone. This experimental
Ellero-Simatos et al. Genome Medicine 2012, 4:94
http://genomemedicine.com/content/4/11/94
Page 2 of 13
setting will be referred as ‘protocol 2’ (Figure S1B in
Additional file 1).
Urine samples were collected over 24 h on day 0 and
day 1. No preservative was added to the urine samples.
Fasting blood samples were collected in the morning of
day 1 and day 2 prior to treatment. Samples were frozen
at -80°C after collection.
Metabolic profiling of urine samples
Sample preparation
Metabolomic analysis of urine samples was conducted by
Metabolon, Inc. (Durham, NC, USA). Osmolality mea-
surements were collected for each sample. Zirconia beads
in a GenoGrinder (2 min, 675 spm (Glen Mills Inc.,
Clifton, NJ, USA)) were used to extract 100 μl of the
urine samples in 400 µL ethyl acetate and ethanol (1:1).
The sample was centrifuged and the liquid phase
removed. The remaining pellet was re-extracted sequen-
tially, with shaking, centrifugation and liquid recovery at
each step, using 200 µL methanol, 200 µL methanol and
water (3:1), and 200 µL dichloromethane and methanol
(1:1). All resultant liquid phases were pooled (approxi-
mately 1 ml), then 225 µL aliquots were dried under
a nitrogen stream in a Zymark TurboVap (Zymark,
Runcorn, UK). The dried samples were then split into
equal parts for analysis on the liquid chromatography-
and gas chromatography-MS platforms as previously
described [12].
Liquid chromatography-MS and gas chromatography-MS
For liquid chromatography-MS analysis, the dried extract
was reconstituted in 100 μl 0.1% formic acid in 10%
methanol. Liquid chromatography-MS was carried out
using a Surveyor HPLC (Thermo-Electron Corporation,
San Jose, CA, USA) with an electrospray ionization
source coupled to a linear trap quadrupole mass spectro-
meter (Thermo-Electron Corporation), which consisted
of an electrospray ionization source and linear ion-trap
mass analyzer. Positive and negative ions were monitored
within a single analysis alternating the ionization polarity
of adjacent scans.
For gas chromatography-MS analysis, the dried extract
was derivatized under dried nitrogen using bis(tri-
methylsilyl)trifluoroacetamide. The gas chromatography
column was 5% phenyl and the temperature ramp was
from 40°C to 300°C in a 16 min period. Samples were
analyzed on a fast-scanning Thermo-Finnigan Trace
DSQ Single Quadrupole mass spectrometer (Thermo-
Electron Corporation) using electron impact ionization.
The instrument was tuned and calibrated daily for mass
resolution and mass accuracy. More details on Meta-
bolon’s liquid chromatography-MS and gas chromato-
graphy-MS platforms can be found in [13]. Data are
available upon request.
Metabolic profiling of serum samples
Targeted metabolic profiling was conducted in serum
samples prepared from fasting blood samples from
volunteers of the placebo and 30 mg groups of protocol 1
and from all volunteers of protocol 2. Seventeen protei-
nogenic amino acids (alanine, arginine, asparagine, aspar-
tic acid, glutamic acid, glutamine, histidine, isoleucine,
leucine, lysine, phenylalanine, proline, serine, threonine,
tryptophan, tyrosine, valine) and 3-methylhistidine were
successfully measured in 5 μl of serum using a targeted
liquid chromatography-MS/MS method adapted from
[14]. Data are available upon request.
Data analysis
Data pretreatment
To account for dilution effects between samples, each
metabolite level in urine was normalized by osmolality
measurement, which had a strong inverse correlation
with total urine volume (R2 = -0.87, P = 10-49, n = 153
samples). Prednisolone had no effect on total urine
volume or osmolality at day 1. However, a significant
increase in the total volume of urine excretion was
observed at day 15 in all treatment groups (P = 0.03),
which did not translate into a significant effect on
osmolality (P = 0.08). Therefore, normalization to
osmolality measurement was preferred to the more clas-
sical normalization to total urine volume. Missing ion
intensity values were assumed to result from areas fall-
ing below the limits of detection. Metabolites with more
than five missing values in one treatment group were
discarded. For each remaining metabolite, the missing
values were imputed with the observed minimum for
that metabolite. In total, 515 peaks were measured in
the urine samples, among which 177 metabolites were
identified and used for subsequent analysis (listed in
Table S1 n Additional file 2).
Principal component analysis
Principal component analysis (PCA) was performed using
R [15] to assess the main sources of variation in metabo-
lite composition of urine samples in volunteers from pro-
tocol 1. To improve visualization, the inter-individual
variation in urinary metabolic composition was removed
by subtracting metabolite concentration at baseline
(day 0) from metabolite concentrations at day 1 and
day 15. Three PCA models were fitted. The first one
included metabolite levels in the urine of volunteers trea-
ted with placebo and 30 mg prednisolone only at day 1
and day 15, the second one included metabolite levels of
volunteers treated with placebo, 7.5 mg, 15 mg or 30 mg
prednisolone at day 1 only and the third one included
metabolite levels of volunteers treated with placebo,
7.5 mg, 15 mg or 30 mg prednisolone at day 15 only.
Metabolites were autoscaled prior to analysis.
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Identification of metabolites significantly changed in
protocol 1
To account for the paired structure of the data (more
than one sample available for each individual), linear
mixed models (LMMs) for repeated measurements were
used to determine which metabolites were significantly
changed in the urine of volunteers after treatment.
LMMs were fitted using SAS (version 9.2, SAS Institute
Inc., Cary, NC, USA), applying the method of residual
maximum likelihood. For each metabolite, a separate
model was built. It included metabolite concentrations
of all individuals with specification of treatment group
(placebo, 7.5 mg prednisolone, 15 mg prednisolone or
30 mg prednisolone), time (day 0, day 1, day 15) and
individual (1, 2, ... 47). The outcome of the LMM was a
global P-value of an F test with the H0 hypothesis that
there is no difference between the mean metabolite con-
centrations of the eight time*treatment interaction
groups. If this global P-value was lower than 0.05, then
additional t tests were performed within the LMM out-
put to test which pairs of time*treatment interaction
groups were statistically significantly different. P-values
of the latter t tests were tested for multiple comparisons
including all metabolites using the false discovery rate
[16] with a significance threshold q <0.05.
In serum, a similar data analysis strategy was used. One
LMM was fitted for each metabolite as previously
described for urine samples, using only placebo and 30 mg
groups.
Identification of metabolites significantly changed in
protocol 2
Because in protocol 2, no placebo group was included,
paired t tests were conducted between metabolite concen-
trations at day 1 and metabolite concentrations at day 0, in
urine and in serum. P <0.05 was considered as significant.
P-values were tested for multiple comparisons including all
metabolites using the false discovery rate with a signifi-
cance threshold q <0.05.
Association between HOMA-IR and urine metabolites
To derive urinary metabolites that significantly corre-
lated with HOMA-IR in protocol 1, partial least squares
(PLS) regression analyses were applied using an in-
house developed algorithm in MatLab version 7.9.0.529
R2009b (The MathWorks Inc., Natick, MA, USA) [17].
Two PLS models were built, regressing urinary MS data
in all volunteers from protocol 1 (n = 47) as indepen-
dent variables at day 1 or day 15 (X matrix) against
HOMA-IR values at day 2 or day 16 (Y matrix) respec-
tively. Metabolites were autoscaled prior to analysis.
The statistical significance of the model performance
and variable selection were assessed with 1,000 permu-
tations of the Y matrix and P <0.05 was considered as
significant
Results
Urinary metabolic profiles
Overview
The dose- and time-dependent effects of prednisolone
treatment were first assessed using protocol 1. In this pro-
tocol, 47 healthy men were treated with prednisolone
(placebo (n = 11), 7.5 mg (n = 11), 15 mg (n = 13) or
30 mg (n = 12)) once daily for 15 days (Figure S1A in
Additional file 1). Urine samples were collected at baseline,
and after one day and 15 days of treatment and submitted
to untargeted metabolic profiling. Figure 1 displays the
overall results of the urine metabolic profiling. The first
PCA model (Figure 1A) shows two diverging metabolic
trajectories for the volunteers treated with 30 mg predni-
solone at day 1 and day 15, whereas this effect was not
seen in the placebo group. The other PCA models illus-
trate that these metabolic trajectories were strongly dose-
dependent, after one day of treatment (Figure 1B), as well
as after 15 days (Figure 1C). Prednisolone therefore
induced both time- and dose-dependent metabolic pertur-
bations in the urine of the volunteers.
Acute prednisolone treatment
After a single dose, prednisolone treatment significantly
disrupted the levels of 31 metabolites in the urine of pro-
tocol 1 volunteers. In the volunteers treated with 7.5 mg,
15 mg and 30 mg prednisolone, 2, 10 and 29 metabolites
were significantly changed, respectively, compared with
placebo (Table 1). This confirmed that the effects of pre-
dnisolone on the urinary metabolic profiles of healthy
volunteers were dose-dependent. Prednisolone treatment
decreased the urinary levels of dehydroepiandrosterone
sulfate (DHEA-S), and strongly increased the levels of
glucose and of metabolites involved in lipid metabolism
such as propionylcarnitine, L-acetylcarnitine and L-car-
nitine. Prednisolone treatment also consistently dose-
dependently increased the urinary levels of 13 proteinogenic
amino acids: lysine, alanine, histidine, methionine,
threonine, proline, serine, leucine, valine, phenylala-
nine, glycine, asparagine and isoleucine.
To evaluate the robustness of these findings in an inde-
pendent cohort, we analyzed the urine samples from pro-
tocol 2 volunteers using the same metabolomic platforms.
In this protocol, six independent healthy men were treated
with placebo at day 0 and with 75 mg prednisolone at day
1 and urine samples were collected at both time-points
(Figure S1B in Additional file 1). Among the 31 metabo-
lites that were selected in protocol 1, 24 were similarly
significantly changed in protocol 2 (Table 1). Therefore,
the rapid effects of prednisolone on urinary amino acids,
glucose, DHEA-S and carnitine derivatives were con-
firmed. Interestingly, we also observed that, among many
others, 3-methylhistidine, a marker for muscle protein
catabolism, was significantly increased in this protocol
Ellero-Simatos et al. Genome Medicine 2012, 4:94
http://genomemedicine.com/content/4/11/94
Page 4 of 13
(Figure 2A). A list of all urinary metabolites significantly
changed during this study, including protocol 2, is pro-
vided in Table S2 in Additional file 3.
Prolonged prednisolone treatment
To assess the difference between a single dose and a
longer therapeutic treatment, the same analysis was con-
ducted on the urinary metabolic profiles of protocol 1
volunteers at day 15. At this time-point, 29 metabolites
were significantly changed (Table 2). Similar to day 1, the
effects of prednisolone on urinary metabolic profiles
were dose-dependent. It is noteworthy that, for some
metabolites, a strong effect was seen in the urine profiles
of volunteers from the placebo group, which made detec-
tion of prednisolone-specific effects less reliable (see for
example metabolites involved in catecholamine metabo-
lism in Table 2). Therefore, later discussion in this paper
will focus only on metabolites for which the effect in the
placebo group was small or prednisolone-specific effects
Figure 1 PCA plots of urinary metabolic profiles. (A) The first PCA model includes metabolic profiles from block 1 volunteers treated with
placebo (black, n = 11) or 30 mg prednisolone (dark red, n = 12) for one day (circle) or 15 days (square). (B) The second PCA model includes
metabolic profiles from block 1 volunteers treated with placebo (black, n = 11) or 7.5 mg (orange, n = 11), 15 mg (pink, n = 13) or 30 mg
(dark red, n = 12) prednisolone for one day. (C) The third PCA model includes metabolic profiles from block 1 volunteers treated with placebo
or prednisolone for 15 days. Arrows represent dose-dependent metabolic trajectories.
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were confirmed in several dose groups, time-points or
matrices. Thus, after 15 days, the effects of prednisolone
on urine glucose and DHEA-S levels observed at day 1
were still present and levels of seven proteinogenic
amino acids (glutamine, histidine, asparagine, threonine,
tryptophan, serine and isoleucine) were still elevated. By
contrast, carnitine derivatives returned to baseline levels
(Table S2 in Additional file 3).
Targeted metabolomics in serum
To exclude kidney failure as the cause of prednisolone-
induced aminoaciduria, we measured proteinogenic amino
acids in serum samples from the volunteers treated with
the highest doses of prednisolone (30 mg and 75 mg)
(Table 3).
After one day of treatment, one proteinogenic amino
acid (alanine) significantly increased in the serum of the
volunteers treated with 30 mg prednisolone compared
with placebo, and 10 (glutamine, alanine, asparagine,
arginine, aspartic acid, phenylalanine, proline, threonine,
tyrosine and tryptophan) increased in the serum of the
volunteers treated with 75 mg prednisolone compared
with baseline levels. After 15 days of treatment, no sig-
nificant change in amino acid concentration was
observed in the serum of volunteers treated with 30 mg
prednisolone compared to placebo.
Because, at least in the highest dose group (75 mg), kidney
failure could then be excluded as the cause of prednisolone-
induced aminoaciduria, levels of 3-methylhistidine, a marker
for muscle protein catabolism, were also investigated in
serum of the same volunteers. In block 1, no significant
difference was seen between 30 mg and placebo groups
(data not shown), whereas in block 2 volunteers, levels of
3-methylhistidine were increased (P = 0.055) (Figure 2B).
Table 1 Metabolites significantly changed in urine of healthy volunteers treated with prednisolone for one day.
Metabolite Protocol 1 Protocol 2
pathway Name HMDB ID Placebo 7.5 mg 15 mg 30 mg 75 mg
Lipid metabolism L-carnitine HMDB00062 1.4 1.9 2.2 9.0*** 8.4***
Propionylcarnitine HMDB00824 1.4 3.0 2.9** 5.2*** 5***
L-acetylcarnitine HMDB00201 1.5 2.4 2.8** 7.1*** 5.9***
Myoinositol HMDB00211 0.9 1.1 1.6 3.2*** 4.5***
Proteinogenic amino acids L-lysine HMDB00182 0.8 1.0 1.6 2.1*** 2.1***
L-alanine HMDB00161 1.1 1.1 1.3* 1.6*** 1.9***
L-histidine HMDB00177 1.0 1.1 1.5 2.4*** 1.9**
L-methionine HMDB00696 1.1 1.3 1.2 1.6*** 1.8***
L-threonine HMDB00167 1.0 1.0 1.2 1.6*** 1.8**
L-proline HMDB00162 1.0 1.2 1.2 1.7*** 1.7**
L-serine HMDB00187 1.0 1.1 1.2 1.5*** 1.7**
L-leucine HMDB00687 1.0 1.2 1.0 1.4*** 1.6*
L-valine HMDB00883 1.0 1.1 1.1 1.4*** 1.5***
L-phenylalanine HMDB00159 1.0 1.2 1.1 1.3*** 1.4***
Glycine HMDB00123 1.0 1.0 1.2 1.4** 1.4**
L-asparagine HMDB00168 0.8 0.9 1.0 1.2*** 1.5
L-isoleucine HMDB00172 1.1 1.1 1.0 1.6** 1.4
Other amino acids 4-guanidinobutanoate HMDB03464 1.2 1.4 1.8 2.8*** 4.0***
Beta-alanine HMDB0056 1.0 1.4* 1.7* 2.2*** 2.8*
Pyroglutamine NA 1.3 1.4 1.4 1.9** 1.9*
L-kynurenine HMDB00684 1.1 1.1 1.6 1.4** 1.3*
Carbohydrate metabolism D-glucose HMDB00122 1.2 1.4 1.5 8.9*** 16.7*
3-hydroxybutyrate HMDB00023 1.0 1.3 1.4* 2.0*** 2.8**
Steroids Dehydroepiandrosterone sulfate HMDB01032 1.3 0.8 0.8* 0.8* 0.4**
Energy metabolism Phosphate HMDB01429 1.2 1.3 0.9** 0.9** 0.9
Nucleotide metabolism Nicotinic acid mononucleotide HMDB01132 1.2 1.4 1.5** 1.3 1.4**
Nicotinamide HMDB01406 1.5 1.5 1.0** 1.0** 1.4
1-methylguanosine HMDB01563 1.0 1.2* 1.1 1.0 1.0
Vitamins and cofactors Pantothenate HMDB00210 1.1 1.3 1.3* 1.3** 1.4***
L-dehydroascorbate HMDB01264 1.1 1.2 1.1 1.2** 1.2
Xenobiotics Mandelic acid HMDB00703 1.0 0.9 1.1 1.4** 0.9
Data represents the mean ratio of metabolite level at day 1 compared with day 0. *P <0.05, **P <0.01,***P <0.001 and q <0.05 compared to placebo group for
protocol 1 using liner mixed models, and compared to day 0 for protocol 2, using paired t tests. HMDB, Human Metabolome Database.
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Urinary biomarkers for prednisolone-induced insulin
resistance
HOMA-IR
Finally, we aimed to evaluate the relationship between the
urinary metabolic perturbations induced by prednisolone
and the development of insulin resistance. HOMA-IR, an
index for measuring insulin resistance, was calculated
in volunteers from protocol 1 at day 2 and at day 16
(Figure 3). HOMA-IR was not perturbed by 7.5 mg pre-
dnisolone at any time-point; 15 mg prednisolone increased
HOMA-IR after 15 days; and 30 mg prednisolone
increased HOMA-IR at day 2 and day 16. Thus, predniso-
lone treatment enhanced insulin resistance in healthy
volunteers in a dose- and time-dependent manner.
Partial least squares regressions
Two PLS regression models were constructed between
metabolite levels in urine and HOMA-IR separately at day
1 and at day 15 (Table 4). Urinary metabolic profiles and
HOMA-IR were significantly correlated at both time-
points (P = 0.015 and P = 0.004 respectively). At day 1, 10
proteinogenic amino acids and two carnitine derivatives
positively correlated to HOMA-IR. At day 15, proline
betaine, tartaric acid, androsterone sulfate, N-methylnico-
tinamide (NMN), pimelic acid, isocitric acid and taurine
negatively correlated with HOMA-IR, whereas L-alanine
and N-acetylvaline positively correlated with HOMA-IR.
Discussion
The present study first aimed at providing an unbiased
description of the metabolic perturbations induced by
prednisolone treatment in human using untargeted urine
metabolic profiling. Development of GC-adverse meta-
bolic effects has mainly been studied with high doses (30
to 60 mg) [18,19]. However, most patients treated with
prednisolone for long periods receive doses lower than
7.5 mg per day and the extent to which these low doses
induce metabolic adverse effects is still unclear. In a
recent study, it has been shown that 7.5 mg prednisolone
daily for 15 days affects multiple pathways of intermedi-
ary metabolism in healthy volunteers [20], however the
observed perturbations were rather small. In the present
study, we provide evidence that both the acute and pro-
longed effects of prednisolone on human metabolism are
strongly dose-dependent. At the lowest therapeutic dose
(7.5 mg), changes in metabolic profiles were indeed
almost nonexistent, even after 15 days of treatment,
whereas in the highest doses (30 mg and 75 mg), urine
metabolic profiles were strongly perturbed after a single
dose.
Moreover, we demonstrate differential metabolic
effects of acute versus prolonged treatment with similar
doses of prednisolone. PCA highlighted two diverging
urinary metabolic trajectories at day 1 and day 15, espe-
cially in the highest dose groups. These findings were
confirmed by more refined statistical analyses, which
highlighted different metabolic pathways for the metabo-
lites disrupted by prednisolone treatment at day 1 and at
day 15. Previous studies have shown differential meta-
bolic effects of single versus repeated dose of GCs. Based
on data obtained from the same clinical trial, Van Raalte
et al. reported that an acute high dose of prednisolone
inhibited insulin secretion in healthy volunteers, whereas
insulin secretion increased at day 15, illustrating that
b-cell function partially recovered following prolonged
exposure [11]. In light of these previous findings, our
new results might also reflect adaptive mechanisms trig-
gered in healthy volunteers under prolonged treatment
with prednisolone.
Figure 2 3-methylhistidine in protocol 2 volunteers. Data
represent metabolite levels (divided by the mean of
3-methylhistidine level detected in this study) in urine (A) and
serum (B) of protocol 2 volunteers before and after a single dose of
prednisolone (75 mg). P-values calculated using paired t tests.
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One of the most important finding of this study was
that prednisolone increased the urinary concentrations
of 13 proteinogenic amino acid after a single dose. In
healthy humans, amino acids are usually almost fully
reabsorbed in the kidney proximal tubules and very low
quantities are excreted in urine. Aminoaciduria only
occurs if kidney transport is affected or if plasmatic con-
centrations increase [21]. Here, aminoaciduria cannot be
attributed to impaired renal amino acid reabsorption,
because protein amino acid levels were also increased in
serum of the volunteers treated with the highest dose of
prednisolone at day 1. Moreover, GCs have previously
been shown to enhance kidney amino acid reabsorption
in rats [22,23].
It is well described that high doses of GCs acutely
induce protein catabolism in healthy young adults [24-26].
Therefore, the simultaneous increase of urine and serum
proteinogenic amino acids in volunteers treated with high
doses of prednisolone observed in our study at day 1
might reflect this catabolic effect of prednisolone. Burt
et al. reported that prednisolone-stimulated protein oxida-
tion does not persist under chronic administration and
that a metabolic adaptation occurs to limit protein loss
[27]. In our study, prednisolone-induced aminoaciduria
only partially persisted after 15 days. A smaller number of
amino acids was indeed significantly increased at day 15
compared to day 1 (7 versus 13 in the 30 mg group),
which suggests partial metabolic adaptation in the healthy
volunteers.
Prolonged exposure to GCs is frequently associated with
marked skeletal muscle atrophy [28] resulting from
decreased protein synthesis and increased protein break-
down [29,30]. In the volunteers of protocol 2, we observed
increased urinary and serum levels of 3-methylhistidine,
an amino acid formed by the methylation of certain histi-
dine residues in the myofibrillar proteins actin and
Table 2 Metabolites significantly changed in urine of healthy volunteers treated with prednisolone for 15 days.
Metabolite pathway Protocol 1
Name HMDB ID Placebo 7.5 mg 15 mg 30 mg
Proteogenic amino acids L-glutamine HMDB00641 0.9 1.5** 4.1* 3.3***
L-histidine HMDB00177 1.2 0.8 1.3 2.3**
L-asparagine HMDB00168 0.9 1.1** 1.3** 1.6***
L-alanine HMDB00161 1.0 1.0 1.3 1.6***
L-threonine HMDB00167 0.9 0.9 1.0* 1.4***
L-tryptophan HMDB00929 1.0 1.1 1.1 1.3***
L-serine HMDB00187 1.0 0.9 1.0 1.2*
L-isoleucine HMDB00172 1.2 0.9 0.9** 1.3
Other amino acids Kynurenate HMDB00715 1.1 0.9 0.8*** 0.9**
Prolyl-4-hydroxyproline HMDB06695 1.1 1.1 0.8** 0.8**
Carbohydrate metabolism D-glucose HMDB00122 1.2 1.4 1.4 5.5*
Gluconate HMDB00625 1.3 1.1 1.0** 0.9***
N-acetylgalactosamine-4-sulfate HMDB00781 1.2 1.0 0.9 0.8***
Sorbitol HMDB00247 1.2 1.0 0.9* 0.8*
Steroids Dehydroepiandrosterone sulfate HMDB01032 0.9 0.2*** 0.2** 0.2***
Energy metabolism Isocitrate HMDB00193 1.1 1.1 0.9* 0.8***
Phosphate HMDB01429 1.1 1.0 0.8* 0.8**
Citrate HMDB00094 1.4 1.0* 1.0** 0.7***
Nucleotide metabolism Nicotinic acid mononucleotide HMDB01132 1.4 1.3 1.0* 0.9*
Pseudouridine HMDB00767 1.1 1.0 1.0 0.9*
N-methylnicotinamide HMDB00699 1.2 0.9 0.6* 0.5**
Vitamins and cofactors Pyridoxine HMDB00239 1.2 0.7** 0.7 0.8**
Xenobiotics Mandelic acid HMDB00703 1.0 1.1 1.0 1.4**
Salicyluric acid HMDB00840 2.5 1.3 1.0** 1.0
Tartaric acid HMDB00956 1.1 1.1 0.9* 0.9
Catecholamine metabolism Homovanillic acid HMDB00118 1.2 0.9* 0.9** 1.0*
Dopamine HMDB00073 1.3 0.9** 0.8*** 0.9**
Vanillylmandelic acid HMDB00291 1.1 1.0 0.9 0.9*
Glycerophospholipid metabolism Ethanolamine HMDB00149 1.0 0.8** 0.8** 0.9*
Data represents the mean ratio of metabolite level at day 15 compared to day 0. *P <0.05, **P <0.01,***P <0.001 and q <0.05 compared to placebo group, using
linear mixed models. HMDB, Human Metabolome Database.
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myosin. In humans, 3-methylhistidine cannot be reused
for muscle protein synthesis when these proteins are bro-
ken down [31] and is not metabolized but rapidly excreted
unchanged in urine [32]. Moreover, because 90% of the
body pool of 3-methylhistidine resides in skeletal muscle
[32] and this tissue contributes as much as 75% to urinary
3-methylhistidine [33], it has been proposed that the mea-
surement of urinary excretion of this amino acid could be
used to assess the rate of breakdown of skeletal muscle
protein [34]. In the present study, rapid increase of 3-
methylhistidine therefore supports the hypothesis that pre-
dnisolone-induced aminoaciduria is an early manifestation
of the well-known GC-induced skeletal muscle atrophy.
However, the fraction of 3-methylhistidine excretion that
can be attributed to skeletal muscle may vary depending
on circumstances, and other sources of 3-methylhistidine
have been reported [35,36]. To measure more quantita-
tively the contribution of prednisolone-induced skeletal
muscle breakdown in healthy individuals, more invasive
measurements such as muscle interstitial 3-methylhisti-
dine concentrations [37] could be performed.
In the clinic, the use of prednisolone in doses of lower
than 10 mg/day is rarely associated with GC-induced
myopathy, whereas higher GC doses result in a more
rapid onset of muscle weakness [38]. Our results are in
agreement with these clinical observations, because we
did not observe any disruption in the urinary amino acid
profiles of healthy volunteers treated with 7.5 mg/day
and the first significant increase in amino acid levels was
observed at 15 mg/day.
Overall, we found that one of the earliest effects of
prednisolone on the metabolism of healthy volunteers
involves amino acid metabolism and that it is most
likely an early manifestation of GC-induced skeletal
muscle wasting. We therefore suggest that urinary meta-
bolomics represents a noninvasive way of monitoring
the effect of GCs on protein catabolism as soon as after
a single dose.
In addition to the effects on amino acids, prednisolone
significantly disrupted the levels of many other urinary
metabolites. For example, we observed that prednisolone
strongly increased the urinary levels of carnitine, acetyl-L-
carnitine and propionylcarnitine at day 1 but not at day
15. These three endogenous compounds are part of the
total carnitine pool. Because more than 90% of the total
body store of carnitine resides within skeletal muscle [39],
these observations could best be explained by the myo-
pathic phenotype induced by prednisolone resulting in the
loss of these three metabolites from the muscle tissue and
subsequent urinary excretion. The fact that the carnitine
derivative levels return to normal after 15 days could
be part of the metabolic adaptation mentioned earlier.
However, the normal physiological role of these metabo-
lites is linked with the oxidation of fatty acids, and their
decreased urinary levels have been shown to be potent
biomarkers for the activation of b-oxidation [40]. Here, a
temporary inhibition of fatty acid oxidation might also be
induced by prednisolone in healthy volunteers. We cannot
rule out the possibility of prednisolone-induced alteration
of carnitine renal reabsorption. Additional studies are
Table 3 Proteinogenic amino acids in serum of healthy volunteers treated with prednisolone.
Metabolite Day 2 Day 16
Name HMDB ID Placebo 30 mg 75 mg Placebo 30 mg
L-glutamine HMDB00641 1.1 1.4 1.6*** 1.5 1.4
L-alanine HMDB00161 1.1 1.3** 1.5*** 1.2 1.3
L-asparagine HMDB00168 1.2 1.3 1.5** 1.2 1.2
L-arginine HMDB00517 1.3 1.0 1.4* 1.5 1.1
L-aspartic acid HMDB00191 1.2 1.1 1.4* 1.3 1.1
L-phenylalanine HMDB00159 1.1 1.1 1.2** 1.1 1.0
L-proline HMDB00162 1.1 1.1 1.2** 1.2 1.2
L-threonine HMDB00167 1.1 1.1 1.2** 1.1 1.0
L-tyrosine HMDB00158 1.2 1.1 1.2* 1.1 1.0
L-tryptophan HMDB00929 1.1 1.2 1.1* 1.2 1.1
L-serine HMDB00187 1.2 1.1 1.3 1.2 1.0
L-histidine HMDB00177 1.1 1.0 1.1 1.1 0.9
L-isoleucine HMDB00172 1.1 1.1 1.1 1.0 0.9
L-lysine HMDB00182 1.2 1.0 1.1 1.1 1.0
L-glutamic acid HMDB00148 1.1 0.9 1.0 1.1 1.0
L-leucine HMDB00687 1.1 1.0 1.0 1.0 0.8
L-valine HMDB00883 1.1 0.9 0.9 1.0 0.9
Data represents the mean ratio of metabolite level at day 2 or day 16 compared with day 1. *P <0.05, **P <0.01,***P <0.001 and q <0.05 compared to placebo
group for protocol 1 using liner mixed models, and compared to day 0 for protocol 2, using paired t tests. HMDB, Human Metabolome Database.
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needed to unravel the possible cause of this transient pre-
dnisolone-induced increase in carnitine derivatives.
We also describe that DHEA-S levels strongly decreased
in the urine of volunteers at day 1 and day 15, even at the
lowest dose (7.5 mg) of prednisolone. DHEA-S is a major
metabolite of DHEA. They are both mainly produced by
the adrenal cortex, and over 99% of DHEA is sulfated
before secretion. Because of its long half-life compared
with DHEA, circulating DHEA-S levels serve as a measure
of integrated adrenal androgen secretion. It is well
described that exogenous GC administration has a pro-
found impact on both DHEA and DHEA-S production
[41]. Therefore, our present findings are not surprising.
However, we show here that urine metabolomics could
already follow adrenal androgen suppression after a single
low dose of prednisolone, as well as its progression over
time, as DHEA-S levels were lower after 15 days than after
one day compared with placebo. Interestingly, decreased
DHEA levels have been implicated in high cholesterol,
inflammation, immune disorders, diabetes and osteoporo-
sis [42,43], and DHEA replacement has attracted consider-
able attention over recent years [44]. However, whether the
prednisolone-induced reduction of DHEA and DHEA-S
levels contributes to prednisolones undesired side effects
remains unknown.
Finally, we demonstrate that the urinary metabolic pro-
files of healthy individuals treated with prednisolone are
significantly correlated to HOMA-IR, a clinical measure of
insulin resistance. Interestingly, metabolites that correlate
to HOMA-IR after a single dose or after 15 days of predni-
solone treatment are different, suggesting that different
metabolic pathways are involved when insulin resistance is
induced by a single high dose of prednisolone treatment
or by repeated treatment.
After one day of prednisolone treatment, urinary levels
of 10 amino acids and two short chain acyl-carnitines
were positively associated with HOMA-IR. Similar meta-
bolic profiles of altered protein and branched-chain
amino acid metabolism have been associated with insulin
resistance in men [45]. Therefore, perturbation of
branched-chain amino acid metabolism is thought to be
an important component in the development of insulin
Figure 3 HOMA-IR n volunteers from protocol 1. (A) Day 2.
(B) Day 16. The black lines represent the mean value. The top and
bottom of the box represent the 75th and 25th percentile. The
whiskers indicate the maximum and minimum points. *P < 0.05
compared to placebo group, using analysis of variance.
Table 4 Summary of partial least squares regressions
between urinary metabolic profiles and HOMA-IR.
Day P Metabolite name HMDB ID R P
Day 1 0.015 L-proline HMDB00162 + 0.002
L-alanine HMDB00161 + 0.003
L-glutamic acid HMDB00148 + 0.006
L-valine HMDB00883 + 0.006
L-leucine HMDB00687 + 0.011
L-serine HMDB00187 + 0.017
Propionylcarnitine HMDB00824 + 0.022
L-phenylalanine HMDB00159 + 0.024
L-isoleucine HMDB00172 + 0.029
L-methionine HMDB00696 + 0.032
L-acetylcarnitine HMDB00201 + 0.044
L-histidine HMDB00177 + 0.045
Day 15 0.004 Tartaric acid HMDB00956 - 0.013
Androsterone sulfate HMDB02759 - 0.013
Proline betaine HMDB04827 - 0.014
N-methylnicotinamide HMDB03152 - 0.016
Pimelic acid HMDB00857 - 0.025
L-alanine HMDB00161 + 0.027
N-acetylvaline HMDB11757 + 0.028
Taurine HMDB00251 - 0.037
Isocitric acid HMDB00193 - 0.05
The sign of the correlation coefficients to the regression axe (R) and P-values
are displayed only for metabolites significantly associated with HOMA-IR.
HMDB, Human Metabolome Database, HOMA-IR, homeostatic model
assessment of insulin resistance.
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resistance and our results suggest that this might also be
the case with regards to GC-induced insulin resistance
after acute treatment.
After 15 days, NMN was the only metabolite that was
both significantly correlated with HOMA-IR and signifi-
cantly decreased by treatment. NMN is a metabolite of
nicotinamide, which is itself a precursor of nicotinamide
adenine dinucleotide. In human and rodent urine, it was
previously found that ‘species demonstrated profound
changes in nucleotide metabolism, including that of NMN
[...], which may provide unique biomarkers for following
type 2 diabetes progression’ [46]. In diabetic individuals,
decreased urinary levels and slower plasma clearance of
NMN after nicotinamide overload have been observed
[47,48]. Nicotinic acid and nicotinamide have been reported
to induce insulin resistance [49,50] and NMN is thought to
trigger this effect. In light of these previous findings and
our results, NMN might therefore represent an interesting
biomarker for prednisolone-induced insulin resistance.
Conclusions
MS-based metabolomics detected time- and dose-depen-
dent changes in the urine of healthy volunteers treated
with prednisolone. After one single dose, a strong aminoa-
ciduria probably reflected GC-induced muscle protein cata-
bolism in the highest dose groups. Metabolic perturbations
differed between acute and prolonged treatment, suggest-
ing adaptive mechanisms. Finally, some urinary metabolites
were significantly associated with HOMA-IR, including
branched-chain amino acids and NMN, which might
represent interesting biomarkers of prednisolone-induced
insulin resistance. This study illustrates that the application
of metabolic profiling can improve our understanding of
GC-induced metabolic side effects, provide early biomar-
kers for them with minimally invasive procedures and
therefore help the development of improved synthetic
GCs. It might also prove useful in the future to monitor,
and ultimately predict, the appearance of GC-induced side
effects on an individual basis.
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a figure illus-
trating the experimental design. Additional data file 2 is a
table listing all metabolites measured in urine samples.
Additional data file 3 is a table listing metabolites signifi-
cantly changed in urine of volunteers of protocols 1 and 2.
Additional material
Additional file 1: Figure S1: Illustration of the experimental design.
(A) Protocol 1. On day 0 at 0800 h, placebo was administered to 47
healthy men. On day 1 at 0800 h, volunteers were randomly assigned to
a treatment with 7.5 mg (n = 11), 15 mg (n = 13) or 30 mg (n = 12) of
prednisolone or with placebo (n = 11). Medication was taken once daily
in the morning for 15 days. A 24 h urine sample was collected at day 0,
day 1 and day 15 and fasting blood samples were collected in the
morning of day 1, day 2 and day 16 prior to treatment. (B) Protocol 2.
On day 0 at 0800 h, placebo was administrated to six healthy men.
On day 1 at 0800 h, volunteers were treated with 75 mg prednisolone.
A 24 h urine sample was collected at day 0 and day 1. Fasting blood
samples were collected in the morning of day 1 and day 2 prior to
treatment.
Additional file 2: Table S1: List of all metabolites detected and
identified in urine of healthy volunteers.
Additional file 3: Table S2: List of all metabolites significantly regulated
in urine of healthy volunteers treated with prednisolone, in protocol 1
and 2. Data represents the mean ratio of metabolite level at day 1 or day
15 compared to day 0. *P < 0.05, **P < 0.01,***P < 0.001 and q < 0.05
compared to placebo group for protocol 1 using LMMs, and compared
to day 0 for protocol 2, using paired t tests.
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